½ÃÀ庸°í¼­
»óǰÄÚµå
1643930

¼¼°èÀÇ Àڱà Á¶ÀÛ±â(UMD) ½ÃÀå(2025-2033³â)

Global Uterine Manipulation Devices Market - 2025-2033

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 158 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ Àڱà Á¶ÀÛ±â(UMD) ½ÃÀå ±Ô¸ð´Â 2024³â¿¡ 2¾ï 9,370¸¸ ´Þ·¯¿¡ À̸£°í, 2033³â¿¡´Â 4¾ï 8,770¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ 2025³â-2033³â¿¡´Â CAGR 5.8%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.

Àڱà Á¶ÀÛ±â´Â ºÎÀΰú ¿Ü°úÀǰ¡ ´Ù¾çÇÑ ÃÖ¼Ò Ä§½À ¹× °³º¹ ¼ö¼ú °úÁ¤¿¡¼­ ÀÚ±ÃÀÇ À§Ä¡, ¾ÈÁ¤È­ ¹× À̵¿À» Áö¿øÇϵµ·Ï ¼³°èµÈ Ư¼ö ¼ö¼ú ±â±¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â º¹°­°æ, ÀÚ±Ã°æ ¹× ±âŸ ºÎÀΰú ¼ö¼ú¿¡¼­ ƯÈ÷ Áß¿äÇϸç, ÀÚ±ÃÀ» Á¤¹ÐÇÏ°Ô ¿òÁ÷¿© ¼ö¼ú Á¢±Ù¼º, ½Ã°¢È­ ¹× Àü¹ÝÀûÀÎ ¼ö¼ú È¿À²¼ºÀ» Çâ»ó½Ãŵ´Ï´Ù. Àڱà Á¶ÀÛ±â´Â ÀÓ»óÀû ¼±È£µµ¿¡ µû¶ó ¹«±Õ¼ºÀ» °­È­ÇÑ ÀÏȸ¿ë ¸ðµ¨°ú ºñ¿ë È¿À²¼ºÀ» À§ÇØ Àç»ç¿ëÀÌ °¡´ÉÇÑ µðÀÚÀÎÀ¸·Î Á¦°øµË´Ï´Ù.

Àڱà Á¶À۱⠼ö¿ä´Â ÃÖ¼Ò Ä§½À ºÎÀΰú ¼ö¼úÀÇ Ã¤Åà Áõ°¡, ¿©¼º °Ç°­ ¹®Á¦¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ¼ö¼ú ±â¼úÀÇ ¹ßÀü¿¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, »çÀ̾𽺴ÙÀÌ·ºÆ®¿¡ °ÔÀçµÈ ±â»ç¿¡ µû¸£¸é ÃÖ¼Ò Ä§½À Àڱà ÀýÁ¦¼ú ½Ã Àڱà Á¶À۱Ⱑ ¼ö¼ú ºÎÀ§¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» °³¼±ÇÏ°í °³º¹¼úÀÇ ·£µå¸¶Å© ¿ªÇÒÀ» ÇÏ´Â °æ¿ì°¡ ¸¹´Ù°í ÇÕ´Ï´Ù. ÀÌÀü ¿¬±¸¿¡ µû¸£¸é Àڱ󻸷¾Ï ÃÖ¼Ò Ä§½À ¼ö¼ú ½Ã Àڱà Á¶À۱⠻ç¿ë·üÀº 42-90%¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ

ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ

ºÎÀΰú ÁúȯÀÇ À¯º´·ü »ó½Â

Àڱà ±ÙÁ¾, Àڱà ³»¸·Áõ ¹× Àڱþϰú °°Àº ºÎÀΰú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Àڱà Á¶À۱⠽ÃÀåÀÇ ¼ºÀåÀ» Å©°Ô ÁÖµµÇϰí ÀÖÀ¸¸ç ¿¹Ãø ±â°£ µ¿¾È ½ÃÀåÀ» ÁÖµµ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº Á¾Á¾ ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Àڱà Á¶ÀÛ±â¿Í °°Àº È¿°úÀûÀÎ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ ±¹¸³À§»ý¿¬±¸¼Ò(NIH)¿¡ µû¸£¸é ÀڱñÙÁ¾À̶ó°íµµ ¾Ë·ÁÁø Àڱà ±ÙÁ¾Àº ´ëºÎºÐ »ý½Ä±â ³»³» ¿©¼ºÀ» ±«·ÓÈ÷¸ç ¹éÀÎ ¿©¼ºÀÇ ÃÖ´ë 70%, ¾ÆÇÁ¸®Ä«°è ¹Ì±¹ÀÎ ¿©¼ºÀÇ 80% À̻󿡼­ ÀÏ»ý µ¿¾È ¹ß°ßµË´Ï´Ù. ÀڱñÙÁ¾ÀÌ ÀÖ´Â ¸¹Àº ¿©¼ºÀº ÀڱñÙÁ¾ ÀýÁ¦¼ú(±ÙÁ¾ Á¦°Å¼ú)À̳ª Àڱà ÀûÃâ¼úÀ» ¹Þ´Âµ¥, ƯÈ÷ º¹°­°æ ¼ö¼ú°ú °°Àº ÃÖ¼Ò Ä§½À ¼ö¼ú¿¡¼­´Â ÃÖÀûÀÇ ¼ö¼ú °á°ú¸¦ À§ÇØ Àڱà Á¶ÀÛ ÀåÄ¡°¡ ÇÊ¿äÇÕ´Ï´Ù.

¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)¿¡ µû¸£¸é ÀÚ±ÃÀûÃâ¼úÀº ¹Ì±¹¿¡¼­ ¿©¼º¿¡°Ô °¡Àå ¸¹ÀÌ ½ÃÇàµÇ´Â ¼ö¼ú Áß Çϳª·Î, ¸Å³â ¾à 60¸¸ °ÇÀÇ ¼ö¼úÀÌ ½ÃÇàµÇ¸ç ÀÌ Áß ¾à 10%°¡ ÀڱðæºÎ º¸Á¸¼úÀ̸ç, ÀڱñÙÁ¾À¸·Î ÀÎÇÑ ¼ö¼úÀÌ »ó´ç¼ö¸¦ Â÷ÁöÇÏ¿© Àڱà Á¶À۱⿡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¼¼°èº¸°Ç±â±¸(WHO)¿¡ µû¸£¸é Àڱ󻸷ÁõÀº Àü ¼¼°è °¡Àӱ⠿©¼º°ú ¼Ò³àÀÇ ¾à 10%(1¾ï 9õ¸¸ ¸í)°¡ ¾Î°í ÀÖÀ¸¸ç, ÀÌ Áß »ó´ç¼ö´Â Áõ»ó °ü¸®³ª °¡ÀÓ·Â º¸Á¸À» À§ÇØ ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÑ »óÅÂÀÔ´Ï´Ù. Àڱ󻸷Áõ ¼ö¼ú¿¡´Â Á¾Á¾ º¹°­°æÀÌ Æ÷ÇԵǸç, ÀÌ °úÁ¤¿¡¼­ Àڱà Á¶À۱⸦ »ç¿ëÇÏ¿© ÀÚ±ÃÀÇ À§Ä¡¸¦ Á¶Á¤ÇÏ°í ¾ÈÁ¤È­ÇÏ¿© Àڱ󻸷 Á¶Á÷À» ½±°Ô Á¦°ÅÇÒ ¼ö ÀÖ½À´Ï´Ù.

¶ÇÇÑ ¹Ì±¹¾ÏÇùȸ´Â 2024³â ¹Ì±¹¿¡¼­ ¾à 67,880°ÇÀÇ ÀڱþÏÀÌ »õ·Î Áø´ÜµÉ °ÍÀ¸·Î ¿¹ÃøÇϰí ÀÖ½À´Ï´Ù. Ä¡·á¿¡´Â Àڱà ÀûÃâ¼ú ¶Ç´Â ¸²ÇÁÀý ÀýÁ¦¼úÀÌ Æ÷ÇԵǸç, Àڱà Á¶ÀÛ ÀåÄ¡´Â ÀÚ±ÃÀ» º¸´Ù ¾ÈÀüÇϰí È¿°úÀûÀ¸·Î Á¦°ÅÇÒ ¼ö ÀÖµµ·Ï ÀÚ±ÃÀÇ À§Ä¡¸¦ Á¶Á¤ÇÏ´Â µ¥ µµ¿òÀ» ÁÝ´Ï´Ù.

±â±¸ °ü·Ã ÇÕº´ÁõÀÇ À§Çè

±â±¸ °ü·Ã ÇÕº´ÁõÀÇ À§ÇèÀº Àڱà Á¶À۱⠽ÃÀåÀÇ ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ·¯ÇÑ ±â±â´Â ¼ö¼ú °úÁ¤ÀÇ Á¤È®¼º°ú È¿À²¼º Ãø¸é¿¡¼­ ÀåÁ¡ÀÌ ÀÖÁö¸¸ Àڱà õ°ø, °¨¿°, ºÎÀûÀýÇÑ ±â±¸ Ãë±Þ°ú °°Àº ÇÕº´ÁõÀº ºÎÁ¤ÀûÀÎ °á°ú¸¦ ÃÊ·¡ÇÒ ¼ö ÀÖÀ¸¸ç, ÀÌ´Â ÀÇ·á ¼­ºñ½º Á¦°øÀÚ°¡ ÀÌ·¯ÇÑ ±â±â¸¦ äÅÃÇÏÁö ¸øÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àڱà õ°øÀº Á¶ÀÛ±â ÆÁÀÌ ½Ç¼ö·Î Àڱú®À» ¶ÕÀ» ¶§ ¹ß»ýÇϸç ÃâÇ÷, °¨¿°, ÁÖº¯ Àå±â ¼Õ»ó°ú °°Àº ½É°¢ÇÑ ÇÕº´ÁõÀ» À¯¹ßÇÒ ¼ö ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ ±¹¸³º¸°Ç¿ø(NIH)¿¡¼­ ½Ç½ÃÇÑ ¿¬±¸¿¡ µû¸£¸é ÃÖ¼Ò Ä§½À Àڱ󻸷¾Ï ¼ö¼ú¿¡¼­ Àڱà Á¶À۱⠻ç¿ë°ú Àڱà õ°ø ¹ß»ý·üÀº 11%¿¡ ´ÞÇÏ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù.

Àڱà Á¶À۱⸦ »ç¿ëÇÒ ¶§ °¨¿°Àº ƯÈ÷ ÀåÄ¡°¡ Á¦´ë·Î ¸ê±ÕµÇÁö ¾Ê¾Ò°Å³ª ½Ã¼ú Áß Àڱð­ÀÌ ¿À¿°µÈ °æ¿ì ¿ì·ÁµÇ´Â ¶Ç ´Ù¸¥ ¹®Á¦ÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ¹Ì±¹ »êºÎÀΰúÇÐȸÁö¿¡ ½Ç¸° ¿¬±¸¿¡ µû¸£¸é º¹°­°æ ¼ö¼úÀÇ ¾à 2-5%¿¡¼­ ¼ö¼ú ºÎÀ§ °¨¿°ÀÌ ¹ß»ýÇÑ´Ù°í ÇÕ´Ï´Ù. ±×·¯³ª ¼ö¼ú µµ±¸¸¦ ºÎÀûÀýÇÏ°Ô »ì±ÕÇÏ´Â °æ¿ì ÀÌ ºñÀ²Àº ´õ ³ô¾ÆÁú ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ½ÃÀå ¼Ò°³¿Í ¹üÀ§

  • º¸°í¼­ÀÇ ¸ñÀû
  • Á¶»ç ¹üÀ§¿Í Á¤ÀÇ
  • Á¶»ç ¹üÀ§

Á¦2Àå °æ¿µÁøÀÇ ÀλçÀÌÆ® ¹× Áß¿ä Æ÷ÀÎÆ®

  • ½ÃÀåÀÇ ÇÏÀ̶óÀÌÆ®¿Í Àü·«Àû Æ÷ÀÎÆ®
  • ÁÖ¿ä µ¿Çâ°ú ¿¹Ãø
  • °³¿ä : À¯Çüº°
  • °³¿ä : ¿ëµµº°
  • °³¿ä : ÃÖÁ¾»ç¿ëÀÚº°
  • °³¿ä : Áö¿ªº°

Á¦3Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • ºÎÀΰú ÁúȯÀÇ ÀÌȯÀ²ÀÇ »ó½Â
    • ¾ïÁ¦¿äÀÎ
      • ±â±¸ °ü·Ã ÇÕº´ÁõÀÇ À§Çè
    • ±âȸ
    • ¿µÇ⠺м®

Á¦4Àå Àü·«Àû ÀλçÀÌÆ®¿Í ¾÷°è Àü¸Á

  • ½ÃÀåÀÇ ¸®´õ¿Í ¼±±¸ÀÚ
    • »õ·Î¿î ¼±±¸ÀÚ¿Í Àú¸í ±â¾÷
    • ÃÖ´ëÀÇ ¸ÅÃâÀ» ÀÚ¶ûÇÏ´Â ºê·£µå¸¦ È®¸³ÇÑ ¸®´õ
    • È®¸³µÈ Á¦Ç°À» °¡Áø ½ÃÀå ¸®´õ
  • ½ÅÈï ½ºÅ¸Æ®¾÷ ±â¾÷°ú ÁÖ¿ä Çõ½Å±â¾÷
  • CXOÀÇ ½ÃÁ¡
  • Ãֽа³¹ß°ú ȹ±âÀûÀÎ
  • »ç·Ê ¿¬±¸, ÁøÇàÁßÀÎ ¿¬±¸
  • ±ÔÁ¦¿Í »óȯÀÇ »óȲ
    • ºÏ¹Ì
    • À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Porter's Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • SWOT ºÐ¼®
  • ¾ð¸ä ¿ä±¸¿Í °¸
  • ½ÃÀå ÁøÀÔ°ú È®´ë¸¦ À§ÇÑ Ãßõ Àü·«
  • ½Ã³ª¸®¿À ºÐ¼® º£½ºÆ® ÄÉÀ̽º, º£À̽º ÄÉÀ̽º, ÃÖ¾ÇÀÇ °æ¿ì ¿¹Ãø
  • °¡°Ý ºÐ¼®°ú °¡°Ý ½ÃÀå ¿ªÇÐ

Á¦5Àå Àڱà Á¶À۱⠽ÃÀå : À¯Çüº°

  • ÀÏȸ¿ë Àڱà Á¶ÀÛ±â
  • Àç»ç¿ë°¡´ÉÇÑ Àڱà Á¶ÀÛ±â

Á¦6Àå Àڱà Á¶À۱⠽ÃÀå : ¿ëµµº°

  • º¹°­°æÇÏÀÚ±ÃÀüÀûÃâ¼ú(TLH)
  • º¹°­°æÇÏÀڱðæºÎÀýÁ¦¼ú(LSH)
  • º¹°­°æÇϰæÁúÀÚ±ÃÀüÀû¼ú(LAVH)
  • õ°ñÁú °íÁ¤¼ú
  • ±âŸ

Á¦7Àå Àڱà Á¶À۱⠽ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • º´¿ø
  • Àü¹®ºÎÀΰú Ŭ¸®´Ð
  • ¿Ü·¡¼ö¼ú¼¾ÅÍ(ASC)
  • ±âŸ

Á¦8Àå Àڱà Á¶À۱⠽ÃÀå : Áö¿ªº° ½ÃÀå ºÐ¼®°ú ¼ºÀå ±âȸ

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ¿Í ½ÃÀå Æ÷Áö¼Å´×

  • °æÀï ±¸µµ °³¿ä¿Í ÁÖ¿ä ½ÃÀå ±â¾÷
  • ½ÃÀå Á¡À¯À² ºÐ¼® ¹× Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·«Àû ÆÄÆ®³Ê½Ê, ÇÕº´, Àμö
  • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í Çõ½ÅÀÇ ÁÖ¿ä ¹ßÀü
  • ±â¾÷ º¥Ä¡¸¶Å·

Á¦10Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • B. Braun Melsungen AG
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í °³¿ä
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
    • SWOT ºÐ¼®
  • CONMED Corporation
  • CooperSurgical Inc.
  • Normedi, a Hologic Company
  • KARL STORZ SE & Co. KG
  • Conkin Surgical Instrument Ltd.
  • Richard Wolf GmbH
  • Purple Surgical
  • Utah Medical Products, Inc.
  • LABORIE MEDICAL TECHNOLOGIES CORP.

Á¦11Àå ÀüÁ¦Á¶°Ç°ú Á¶»ç ¹æ¹ý

  • µ¥ÀÌÅÍ ¼öÁý ¹æ¹ý
  • µ¥ÀÌÅÍÀÇ »ï°¢Ãø·®
  • ¿¹Ãø ±â¼ú
  • µ¥ÀÌÅÍ °ËÁõ

Á¦12Àå ºÎ·Ï

HBR 25.02.21

The global uterine manipulation devices market reached US$ 293.7 million in 2024 and is expected to reach US$ 487.7 million by 2033, growing at a CAGR of 5.8% during the forecast period 2025-2033.

Uterine manipulation devices are specialized surgical instruments designed to assist gynecological surgeons in positioning, stabilizing, and mobilizing the uterus during various minimally invasive and open surgical procedures. These devices are particularly critical in laparoscopic, hysteroscopic and other gynecological surgeries, enabling precise uterine movement to enhance surgical access, visualization, and overall procedural efficiency. Uterine manipulators are available in single-use (disposable) models for enhanced sterility and reusable designs for cost-effectiveness, depending on clinical preferences.

The demand for uterine manipulation devices is driven by the increasing adoption of minimally invasive gynecological surgeries, a growing awareness of women's health issues and advancements in surgical technologies. For instance, according to the article publised by the ScienceDirect, a uterine manipulator is frequently utilized during a minimally invasive hysterectomy to improve access to the surgical field and serve as a landmark for colpotomy. Prior studies have indicated rates of uterine manipulator use between 42-90 % during minimally invasive surgeries for endometrial cancer.

Market Dynamics: Drivers & Restraints

Rising prevalence of gynecological disorders

The rising prevalence of gynecological disorders such as uterine fibroids, endometriosis and uterine cancer is significantly driving the growth of the uterine manipulation devices market and is expected to drive the market over the forecast period. As these conditions often require surgical intervention, the demand for effective tools, such as uterine manipulators, has risen.

According to the National Institute of Health (NIH), Uterine leiomyomas also known as fibroids, mostly afflict women throughout their reproductive years and are detected in up to 70% of white women and more than 80% of African-American women over their lifespan. Many women with fibroids undergo myomectomy (fibroid removal) or hysterectomy, both of which require uterine manipulation devices for optimal surgical outcomes, especially in minimally invasive procedures like laparoscopic surgeries.

For instance, according to the National Institute of Health (NIH), hysterectomy is one of the most common surgeries performed in women in the United States, totaling roughly 600,000 procedures each year, with approximately 10% of procedures being subtotal (cervix-preserving) and a significant number of these surgeries are due to fibroids, creating demand for uterine manipulators.

According to the World Health Organization (WHO), endometriosis affects roughly 10% (190 million) of reproductive-age women and girls globally, with a significant percentage requiring surgical intervention for symptom management or fertility preservation. Surgery for endometriosis often involves laparoscopy, during which uterine manipulation devices are used to reposition and stabilize the uterus, facilitating the removal of endometrial tissue.

Additionally, the American Cancer Society forecasts for cancer of the uterus in the United States in 2024 approximately 67,880 new cases of uterine cancer will be diagnosed. Treatment often involves hysterectomy or lymphadenectomy, where uterine manipulation devices assist in positioning the uterus for safer and more effective surgical removal.

Risk of device-related complications

The risk of device-related complications is expected to hamper the growth of the uterine manipulation devices market. Despite the advantages these devices offer in terms of precision and efficiency during surgical procedures, complications such as uterine perforation, infection, and improper device handling can lead to adverse outcomes, which may deter healthcare providers from adopting these devices.

Uterine perforation occurs when the manipulator tip inadvertently punctures the uterine wall, leading to significant complications such as bleeding, infection, and injury to surrounding organs. For instance, according to the study conducted by the National Institute of Health (NIH), the use of uterine manipulators and uterine perforation in minimally invasive endometrial cancer surgery study found a uterine perforation rate of 11%.

Infection is another concern when using uterine manipulation devices, particularly when the device is not properly sterilized or if the uterine cavity is contaminated during the procedure. For instance, according to a study in the American Journal of Obstetrics & Gynecology, surgical site infections occur in about 2-5% of laparoscopic surgeries. However, this rate can increase in the case of improper sterilization of surgical tools.

Segment Analysis

The global uterine manipulation devices market is segmented based on type, application, end-user and region.

Application:

The total laparoscopic hysterectomy (TLH) segment is expected to dominate the uterine manipulation devices market share

Total laparoscopic hysterectomy (TLH) is a minimally invasive surgical procedure used to remove the uterus, and it is the dominant segment in the uterine manipulation devices market. The increasing preference for TLH, due to its numerous advantages over traditional open surgery, such as reduced recovery time, lower risk of complications, and better cosmetic outcomes, has made it a key driver of demand for uterine manipulation devices.

The demand for uterine manipulation devices in TLH is particularly high because these devices enhance the precision of the surgery by stabilizing and positioning the uterus, which is vital for laparoscopic access. For instance, according to the American College of Obstetricians and Gynecologists, 70-80% of hysterectomies in the U.S. are now performed laparoscopically, with TLH being the preferred method, further driving the growth of uterine manipulation devices in this segment.

The adoption rate of TLH is growing due to its many advantages over abdominal hysterectomy, such as faster recovery time, less blood loss, and fewer post-operative complications. As more hospitals and clinics adopt TLH as the standard for hysterectomy, the use of uterine manipulation devices has correspondingly increased. For instance, in the U.S., TLH procedures increased by over 15% annually from 2010 to 2020, and this growth is expected to continue as TLH becomes the preferred method for hysterectomy worldwide.

Geographical Analysis

North America is expected to hold a significant position in the uterine manipulation devices market share

North America especially the United States performs hundreds of thousands of hysterectomies annually, the majority of which are now laparoscopic procedures. With TLH being the most common method, uterine manipulation devices are in high demand to ensure the success and precision of these surgeries. For instance, according to the National Institute of Health (NIH), hysterectomy is one of the most common surgeries performed in women in the United States, with 600,000 procedures each year.

North American medical device manufacturers are leaders in developing and improving uterine manipulation devices, incorporating advanced features such as better ergonomics, user-friendly interfaces, and enhanced safety features. This innovation attracts hospitals and surgical centers in the region to adopt these devices more frequently.

For instance, leading manufacturers in North America, like CooperSurgical, produce high-quality uterine manipulators that are widely used in TLH procedures across the region. The RUMI II manipulator is a notable example, widely adopted in U.S. hospitals for its advanced design and effectiveness in TLH.

Asia-Pacific is growing at the fastest pace in the uterine manipulation devices market

In Asia-Pacific, especially in Japan, China and India, laparoscopic surgery, including total laparoscopic hysterectomy, is becoming the preferred method for hysterectomy in the region due to its minimally invasive nature, which reduces recovery times and healthcare costs. As more surgeons and hospitals in the region adopt minimally invasive techniques, the demand for uterine manipulators, which are essential in laparoscopic procedures, has surged.

For instance, according to the National Institute of Health, in Japan, over 50% of hysterectomies are now performed laparoscopically, and this trend is rapidly growing across other APAC nations. In China, laparoscopic hysterectomy adoption rates have increased by 18-20% annually over the past decade.

The Asia-Pacific region is becoming a global hub for medical tourism, with countries like Thailand, India, and Malaysia attracting patients for affordable, high-quality medical procedures. Many of these patients undergo laparoscopic surgeries, which require uterine manipulation devices. The increase in surgical volume, driven by medical tourism and local patients, boosts the demand for uterine manipulators, particularly in countries with established medical tourism industries.

Competitive Landscape

The major global players in the uterine manipulation devices market include B. Braun Melsungen AG, CONMED Corporation, CooperSurgical Inc., Normedi, a Hologic Company, KARL STORZ SE & Co. KG, Conkin Surgical Instrument Ltd., Richard Wolf GmbH, Purple Surgical, Utah Medical Products, Inc., LABORIE MEDICAL TECHNOLOGIES CORP. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global uterine manipulation devices market report delivers a detailed analysis with 62 key tables, more than 54 visually impactful figures, and 158 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Gynecological Disorders
    • 3.1.2. Restraints
      • 3.1.2.1. Risk of Device-Related Complications
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. SWOT Analysis
  • 4.10. Unmet Needs and Gaps
  • 4.11. Recommended Strategies for Market Entry and Expansion
  • 4.12. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.13. Pricing Analysis and Price Dynamics

5. Uterine Manipulation Devices Market, By Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 5.1.2. Market Attractiveness Index, By Type
  • 5.2. Disposable Uterine Manipulators*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Reusable Uterine Manipulators

6. Uterine Manipulation Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Total Laparoscopy Hysterectomy (TLH) *
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Laparoscopic Supracervical Hysterectomy (LSH)
  • 6.4. Laparoscopically Assisted Vaginal Hysterectomy (LAVH)
  • 6.5. Sacrocolpopexy
  • 6.6. Others

7. Uterine Manipulation Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialized Gynecology Clinics
  • 7.4. Ambulatory Surgical Centers
  • 7.5. Others

8. Uterine Manipulation Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. B. Braun Melsungen AG*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. CONMED Corporation
  • 10.3. CooperSurgical Inc.
  • 10.4. Normedi, a Hologic Company
  • 10.5. KARL STORZ SE & Co. KG
  • 10.6. Conkin Surgical Instrument Ltd.
  • 10.7. Richard Wolf GmbH
  • 10.8. Purple Surgical
  • 10.9. Utah Medical Products, Inc.
  • 10.10. LABORIE MEDICAL TECHNOLOGIES CORP.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦